Download pdf
Application of psilocybin in mental health disorders
- 1 University of British Columbia
* Author to whom correspondence should be addressed.
Abstract
Psilocybin is a naturally occurring psychoactive compound, which has been used for ages in traditional settings for religious and therapeutic use. Recent studies have renewed interest in psilocybin for its potential therapeutic benefits in treating depression and anxiety. The pharmacodynamics of psilocybin are complex, involving its rapid conversion to psilocin and its activity on various serotonin receptors, particularly the 5HT2A/C and 5HT1A receptors. In addition, psilocybin can increase glutamate release, which is believed to be an important mechanism underlying its therapeutic effects. Clinical trials have demonstrated that psilocybin has a long-lasting antidepressant effect, with little to no side effects. However, it is necessary to further study the mechanisms underlying its therapeutic potential and to optimize its use in clinical settings. Overall, the promising findings suggest that psilocybin may offer a valuable alternative to traditional antidepressant therapies for individuals suffering from depression and anxiety. Meanwhile, studies have shown that this drug also has certain benefits for mental disorders such as addiction and obsessive-compulsive disorder. Thus, it is necessary to continue exploring the potential of psilocybin as a novel strategy in treating mental health disorders.
Keywords
psilocybin, mental health disorders, application
[1]. Passie, T., Seifert, J., Schneider, U., & Emrich, H. M. (2006). The pharmacology of Psilocybin. Addiction Biology, 7(4), 357–364.
[2]. Nichols, D. E. (2004). Hallucinogens. Pharmacology & Therapeutics, 101(2), 131-181.
[3]. Horita, A., & Weber, L. J. (1962). Dephosphorylation of psilocybin in the intact mouse. Toxicology and Applied Pharmacology, 4(6), 730-737.
[4]. Sellers, E. M., Romach, M. K., & Leiderman, D. B. (2018). Studies with psychedelic drugs in human volunteers. Neuropharmacology, 142, 116–134.
[5]. Ray TS (2010) Psychedelics and the Human Receptorome. PLoS ONE 5(2): e9019.
[6]. Vollenweider, Franz X.1,3; Vollenweider-Scherpenhuyzen, Margreet F. I.2; Bäbler, Andreas1; Vogel, Helen1; Hell, Daniel1 Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action, NeuroReport: December 1, 1998 - Volume 9 - Issue 17 - p 3897-3902
[7]. González-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., Sealfon, S. C., & Gingrich, J. A. (2007). Hallucinogens Recruit Specific Cortical 5-HT2A Receptor-Mediated Signaling Pathways to Affect Behavior. Neuron, 53(3), 439-452.
[8]. Leor Roseman, Lysia Demetriou, Matthew B. Wall, David J. Nutt, Robin L. Carhart-Harris, Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression, Neuropharmacology, Volume 142, 2018, Pages 263-269.
[9]. Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., Taylor, D., Pilling, S., Curran, V.H., & Nutt, D. J. (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The lancet. Psychiatry, 3(7), 619–627.
[10]. Nichols, D. E., Johnson, M. W., & Nichols, C. D. (2016). Psychedelics as medicines: An emerging new paradigm. Clinical Pharmacology & Therapeutics, 101(2), 209–219.
[11]. Carhart-Harris, R. L., Bolstridge, M., Day, C. M., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., Rickard, J. A., Forbes, B., Feilding, A., Taylor, D., Curran, H. V., & Nutt, D. J. (2017). Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up.
[12]. Agin-Liebes, G. I., Malone, T., Yalch, M. M., Mennenga, S. E., Ponté, K. L., Guss, J., Bossis, A. P., Grigsby, J., Fischer, S., & Ross, S. (2020). Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. Journal of Psychopharmacology, 34(2), 155–166.
[13]. Roseman, L., Demetriou, L., Wall, M. B., Nutt, D. J., & Carhart-Harris, R. L. (2018). Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression. Neuropharmacology, 142, 263–269.
[14]. Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., Forbes, M., … Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. The New England journal of medicine, 387(18), 1637–1648.
[15]. Johnson, M. W., & Griffiths, R. R. (2017). Potential therapeutic effects of psilocybin. Neurotherapeutics, 14(3), 734–740.
[16]. Lowe, H., Toyang, N., Steele, B., Valentine, H., Grant, J., Ali, A., Ngwa, W., & Gordon, L. (2021). The therapeutic potential of psilocybin. Molecules, 26(10), 2948.
[17]. van der Meer PB, Fuentes JJ, Kaptein AA, Schoones JW, de Waal MM, Goudriaan AE, Kramers K, Schellekens A, Somers M, Bossong MG, Batalla A. Therapeutic effect of psilocybin in addiction: A systematic review. Front Psychiatry. 2023 Feb 9;14:1134454.
[18]. Ehrmann, K., Allen, J. J. B., & Moreno, F. A. (2022). Psilocybin for the Treatment of Obsessive-Compulsive Disorders. Current topics in behavioral neurosciences, 56, 247–259.
[19]. Gable, R. S. (2004). Comparison of acute lethal toxicity of commonly abused psychoactive substances. Addiction, 99(6), 686–696.
[20]. Gable, R. S. (1993). Toward a comparative overview of dependence potential and acute toxicity of psychoactive substances used nonmedically. The American Journal of Drug and Alcohol Abuse, 19(3), 263–281.
[21]. Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S., MacLean, K. A., Jesse, R., Johnson, M. W., Griffiths, R. R. (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of psychopharmacology (Oxford, England). Retrieved February 17, 2022.
[22]. Prouzeau, D., Conejero, I., Voyvodic, P. L., Becamel, C., Abbar, M., & Lopez-Castroman, J. (2022). Psilocybin efficacy and mechanisms of action in major depressive disorder: A Review. Current Psychiatry Reports.
Cite this article
Chen,J. (2023).Application of psilocybin in mental health disorders.Theoretical and Natural Science,21,173-179.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content
About volume
Volume title: Proceedings of the 3rd International Conference on Biological Engineering and Medical Science
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).